Always worth looking at how other companies are funding and partnerships to advance their products
Sanotize has had some success to be used in trial 2b with organisation set up in EU to find preventatives and treatments
This may help all products using innovative chemistry and application methods
They also had some small early finding from US DOD from memory
https://www.ecraid.eu/news/ecraid-prime-and-sanotize-begin-trial-antiviral-nasal-spray
https://sanotize.com/investors/newsroom/press-releases/ECRAID-Prime and SaNOtize Research and Development Corp. have signed a collaboration agreement to begin the first study of SaNOtize’s antiviral nitric oxide nasal spray (NONSTM), using Europe’s adaptive platform trial in primary care.
The Phase 2B study is set to begin recruitment in Q3/4 2023 and aims to assess the efficacy of NONS versus intranasal saline in patients with COVID-19 and COVID-like illness. The study will be conducted in seven European countries: Belgium, France, Germany, Ireland, Poland, Spain, and the UK
The study aims to enrol 1,000 patients, which will be recruited across general practices in Europe.
Revolutionising our approach to new treatments
ECRAID-Prime’s adaptive platform trial for new COVID-19 and/or COVID-like-illness treatments in primary care could revolutionise the way countries and healthcare systems approach treatments. By using an adaptive platform trial design, this study enables more flexible and efficient clinical research compared to more traditional clinical trial designs. This approach allows for swift adaptation and modification based on emerging data, empowering healthcare providers to refine their strategies and respond more effectively to future outbreaks or pandemics, ultimately reducing mortality rates.
About ECRAID-Prime
ECRAID-Prime is one of the six projects funded by the European Commission's Horizon Europe program to drive therapeutic and vaccines clinical trials to boost COVID-19 treatment and prevention. Launched in December 2021, it will be the first-of-its-kind European Adaptive Platform Trial to assesses therapeutics for COVID-19 and COVID-like-illness in the primary care setting. Ecraid is one of six partners for the project. It is a not-for-profit clinical research foundation dedicated to reducing the impact of infectious diseases in Europe.
About SaNOtize
SaNOtize Research & Development Corp. is a pharmaceutical company based in Vancouver, BC, commercializing the multi-faceted antimicrobial properties of a liquid producing nitric oxide. The company has developed and patented a Nitric Oxide Releasing Solution platform technology (NORS™) to treat and prevent upper respiratory and topical infections. For more information, visit www.SaNOtize.com.
- Forums
- ASX - By Stock
- Viraleze Availability in UK (or lack of)
Always worth looking at how other companies are funding and...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.06M |
Open | High | Low | Value | Volume |
9.6¢ | 9.8¢ | 9.5¢ | $20.94K | 217.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 156052 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.8¢ | 277202 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 156052 | 0.095 |
2 | 305855 | 0.094 |
2 | 320000 | 0.093 |
1 | 100000 | 0.092 |
2 | 149413 | 0.091 |
Price($) | Vol. | No. |
---|---|---|
0.098 | 277202 | 2 |
0.100 | 100000 | 1 |
0.105 | 143467 | 2 |
0.110 | 183058 | 5 |
0.115 | 109827 | 3 |
Last trade - 16.10pm 05/09/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |